{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:22:07Z","timestamp":1768868527430,"version":"3.49.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clon.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T08:58:53Z","timestamp":1525510733000},"page":"472-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature"],"prefix":"10.1016","volume":"30","author":[{"given":"P.J.","family":"Hoskins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2018.04.004_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A\u00a0strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.clon.2018.04.004_bib3","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2018.04.004_bib4","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clon.2018.04.004_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1097-2765(00)80035-0","article-title":"Involvement of Brca2 in DNA repair","volume":"1","author":"Patel","year":"1998","journal-title":"Mol Cell"},{"key":"10.1016\/j.clon.2018.04.004_bib6","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1093\/emboj\/20.17.4704","article-title":"Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences","volume":"20","author":"Tutt","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.clon.2018.04.004_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","article-title":"Brca1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.clon.2018.04.004_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","article-title":"BRCA2 is required for homology-directed repair of chromosomal breaks","volume":"7","author":"Moynahan","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.clon.2018.04.004_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13053-015-0038-x","article-title":"The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers","volume":"13","author":"Cavanagh","year":"2015","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.clon.2018.04.004_bib10","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2018.04.004_bib13","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib14","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2018.04.004_bib15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.clon.2018.04.004_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib18","first-page":"1059","article-title":"Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families","volume":"60","author":"Levy-Lahad","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib19","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2018.04.004_bib20","first-page":"178","article-title":"Ovarian carcinoma histotypes: their emergence as important prognostic and predictive markers","volume":"30","author":"Gilks","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.clon.2018.04.004_bib21","first-page":"166","article-title":"Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer","volume":"30","author":"Ramalingam","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.clon.2018.04.004_bib22","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib23","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/1078-0432.CCR-1029-3","article-title":"Pathology of ovarian cancers in BRCA1 and BRCA2 carriers","volume":"10","author":"Lakhani","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2018.04.004_bib24","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1038\/srep04026","article-title":"Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status","volume":"4","author":"Cunningham","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.clon.2018.04.004_bib25","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1158\/1055-9965.EPI-13-0391","article-title":"Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium","volume":"22","author":"Kobel","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clon.2018.04.004_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/path.2659","article-title":"Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma","volume":"220","author":"Madore","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clon.2018.04.004_bib27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/PAS.0b013e318164edf7","article-title":"Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases","volume":"32","author":"Han","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clon.2018.04.004_bib28","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","article-title":"Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma","volume":"39","author":"Gilks","year":"2008","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.clon.2018.04.004_bib29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/his.12349","article-title":"Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry","volume":"64","author":"Kobel","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.clon.2018.04.004_bib30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0b013e3181e1a3bb","article-title":"Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study","volume":"34","author":"Kobel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clon.2018.04.004_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib32","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2018.04.004_bib33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2018.04.004_bib34","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib37","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2018.04.004_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5508","article-title":"Results of ARIEL2: a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis","volume":"33","author":"McNeish","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib39","article-title":"A\u00a0phase 2 open-label multicentre study of single agent rucarparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation","author":"Shapira-Frommer","year":"2015","journal-title":"Eur Cancer Congress"},{"key":"10.1016\/j.clon.2018.04.004_bib40","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib42","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2018.04.004_bib43","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.clon.2018.04.004_bib44","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm) [abstract]","volume":"15","author":"Ledermann","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2017.03.505","article-title":"Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study","volume":"145","author":"Pujade-Lauraine","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib46","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib47","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/cncr.23425","article-title":"Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib48","first-page":"10","article-title":"Cancer statistics 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2018.04.004_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(10)62231-3","article-title":"Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995\u20132007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data","volume":"377","author":"Coleman","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib50","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/AOG.0000000000000854","article-title":"Trends in relative survival for ovarian cancer from 1975 to 2011","volume":"125","author":"Wright","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clon.2018.04.004_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.07.098","article-title":"Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992\u20132005: a population-based study","volume":"123","author":"Akhtar-Danesh","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib52","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ygyno.2012.02.033","article-title":"Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands","volume":"125","author":"van Altena","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib53","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","article-title":"Ten-year relative survival for epithelial ovarian cancer","volume":"120","author":"Baldwin","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clon.2018.04.004_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/IGC.0b013e3181991b13","article-title":"A\u00a0population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors","volume":"19","author":"Akeson","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib55","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib56","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","article-title":"A\u00a0randomized study of screening for ovarian cancer: a multicenter study in Japan","volume":"18","author":"Kobayashi","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib57","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2018.04.004_bib58","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib59","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1016\/S0140-6736(16)30846-7","article-title":"Ovarian cancer screening: UKCTOCS trial","volume":"387","author":"Thornton","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib60","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/S0140-6736(16)30848-0","article-title":"Ovarian cancer screening: UKCTOCS trial","volume":"387","author":"Hoskins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ygyno.2016.02.020","article-title":"Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial","volume":"141","author":"Narod","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib62","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/S0140-6736(16)30847-9","article-title":"Ovarian cancer screening: UKCTOCS trial","volume":"387","author":"Sasieni","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib63","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2018.04.004_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/M13-1684","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation","volume":"160","author":"Nelson","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clon.2018.04.004_bib65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2018.04.004_bib66","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3816\/CBC.2007.n.053","article-title":"Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers","volume":"7","author":"Friebel","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.clon.2018.04.004_bib68","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2018.04.004_bib69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PAT.0000000000000291","article-title":"The secondary Mullerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters","volume":"47","author":"Singh","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.clon.2018.04.004_bib70","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/cge.12405","article-title":"Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida","volume":"87","author":"Vadaparampil","year":"2015","journal-title":"Clin Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib71","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajmg.a.30577","article-title":"Genetic counseling for BRCA1\/2: a randomized controlled trial of two strategies to facilitate the education and counseling process","volume":"134A","author":"Wang","year":"2005","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib72","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/gim.2014.125","article-title":"Disparities in uptake of BRCA1\/2 genetic testing in a randomized trial of telephone counseling","volume":"17","author":"Butrick","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.clon.2018.04.004_bib73","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2008.10.007","article-title":"Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study","volume":"112","author":"Metcalfe","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib74","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/IGC.0b013e318280f2b4","article-title":"Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?","volume":"23","author":"Powell","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib75","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/IGC.0000000000000907","article-title":"Genetics consultation rates following a diagnosis of high grade serous ovarian carcinoma in the Canadian Province of Ontario","volume":"27","author":"McGee","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib76","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2013.05.003","article-title":"Keeping it simple: genetics referrals for all invasive serous ovarian cancers","volume":"130","author":"Demsky","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib77","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000431352","article-title":"Referral of ovarian cancer patients for genetic counselling by oncologists: need for improvement","volume":"18","author":"Ricci","year":"2015","journal-title":"Public Health Genom"},{"key":"10.1016\/j.clon.2018.04.004_bib78","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/IGC.0000000000000148","article-title":"Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system","volume":"24","author":"Petzel","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib79","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","article-title":"Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","volume":"115","author":"Meyer","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clon.2018.04.004_bib80","first-page":"156","article-title":"Genetic counselling referral rates and uptake of BRCA1 and BRCA2 testing among women diagnosed with serous ovarian cancer in a tertiary care cancer centre","volume":"4","author":"Bell","year":"2013","journal-title":"J\u00a0Genet Syndr Gene Ther"},{"key":"10.1016\/j.clon.2018.04.004_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clon.2018.04.004_bib82","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2015.03.057","article-title":"The sooner the better: genetic testing following ovarian cancer diagnosis","volume":"137","author":"Fox","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib83","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12325-016-0281-1","article-title":"Selecting patients with ovarian cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review","volume":"33","author":"Eccles","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.clon.2018.04.004_bib84","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2008.21.4684","article-title":"Preventing future cancers by testing women with ovarian cancer for BRCA mutations","volume":"28","author":"Kwon","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"SGO Clinical Practice Committee","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib86","series-title":"NCCN clinical practice guidelines in oncology. Genetic\/familial high risk assessment: breast and ovarian version 1","author":"National Comprehensive Cancer Network (NCCN)","year":"2016"},{"key":"10.1016\/j.clon.2018.04.004_bib87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1258\/1357633011937191","article-title":"Telemedicine and clinical genetics: establishing a successful service","volume":"7","author":"Gattas","year":"2001","journal-title":"J\u00a0Telemed Telecare"},{"key":"10.1016\/j.clon.2018.04.004_bib88","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2015.65.9557","article-title":"Randomized noninferiority trial of telephone delivery of BRCA1\/2 genetic counseling compared with in-person counseling: 1 year follow-up","volume":"24","author":"Kinney","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib89","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10897-013-9655-6","article-title":"Models of service delivery for cancer genetic risk assessment and counseling","volume":"23","author":"Trepanier","year":"2014","journal-title":"J\u00a0Genet Counsel"},{"key":"10.1016\/j.clon.2018.04.004_bib91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2008.06.016","article-title":"What women with ovarian cancer think and know about genetic testing","volume":"111","author":"Lacour","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib92","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2011.09.040","article-title":"There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer","volume":"124","author":"Meiser","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib93","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000441714","article-title":"Current status of the management of hereditary breast and ovarian cancer in Asia: first report by the Asian BRCA Consortium","volume":"19","author":"Nakamura","year":"2016","journal-title":"Public Health Genom"},{"key":"10.1016\/j.clon.2018.04.004_bib94","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10897-014-9746-z","article-title":"BRCA genetic counseling among at-risk Latinas in New York City: new beliefs shape new generation","volume":"24","author":"Sussner","year":"2015","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.clon.2018.04.004_bib95","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s13187-014-0740-9","article-title":"What black women know and want to know about counseling and testing for BRCA1\/2","volume":"30","author":"Adams","year":"2015","journal-title":"J\u00a0Cancer Educ"},{"key":"10.1016\/j.clon.2018.04.004_bib96","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaoncol.2015.3048","article-title":"Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study","volume":"1","author":"Armstrong","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10549-011-1449-7","article-title":"Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers","volume":"129","author":"Dhar","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2018.04.004_bib98","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/jmg.2004.030296","article-title":"Hereditary breast\/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians","volume":"42","author":"Wideroff","year":"2005","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amepre.2010.09.027","article-title":"Awareness and utilization of BRCA1\/2 testing among U.S. primary care physicians","volume":"40","author":"Bellcross","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.clon.2018.04.004_bib100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ypmed.2013.06.022","article-title":"Knowledge, attitudes and behavior of physicians regarding predictive genetic tests for breast and colorectal cancer","volume":"57","author":"Marzuillo","year":"2013","journal-title":"Prev Med"},{"key":"10.1016\/j.clon.2018.04.004_bib101","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10897-012-9504-z","article-title":"Attitudes and practices among internists concerning genetic testing","volume":"22","author":"Klitzman","year":"2013","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.clon.2018.04.004_bib102","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serious ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib103","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-017-4181-0","article-title":"Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients","volume":"163","author":"Crawford","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2018.04.004_bib104","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/jmedgenet-2015-103452","article-title":"Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families","volume":"53","author":"Li","year":"2016","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib105","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/cancers7040874","article-title":"Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges","volume":"7","author":"Rajyalakshmi","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2018.04.004_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12907-015-0004-6","article-title":"A\u00a0reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilizing multiplex PCR-based targeted next generation sequencing","volume":"15","author":"Ellison","year":"2015","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.clon.2018.04.004_bib107","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/humu.23137","article-title":"Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas","volume":"38","author":"Weren","year":"2017","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.clon.2018.04.004_bib108","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00428-016-1919-8","article-title":"NGS-based BRCA 1\/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial","volume":"416","author":"Endris","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clon.2018.04.004_bib109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00001622-199701000-00014","article-title":"The BRCA1 and BRCA2 breast cancer genes","volume":"9","author":"Casey","year":"1997","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib110","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1001\/jama.1996.03530480027036","article-title":"BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes","volume":"275","author":"Lerman","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2018.04.004_bib111","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1099-1611(200011\/12)9:6<504::AID-PON491>3.0.CO;2-R","article-title":"Uptake of hereditary breast\/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network","volume":"9","author":"Julian-Reynier","year":"2000","journal-title":"Psychooncology"},{"key":"10.1016\/j.clon.2018.04.004_bib112","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/A:1025864703405","article-title":"Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway","volume":"12","author":"Bodd","year":"2003","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.clon.2018.04.004_bib113","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/109065703322537241","article-title":"Testing participation in BRCA1\/2-positive families: initiator role of index cases","volume":"7","author":"Blandy","year":"2003","journal-title":"Genet Test"},{"key":"10.1016\/j.clon.2018.04.004_bib114","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.ejhg.5201206","article-title":"BRCA1\/2 predictive testing: a study of uptake in two centres","volume":"12","author":"Brooks","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10689-004-7991-2","article-title":"Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients","volume":"4","author":"Landsbergen","year":"2005","journal-title":"Fam Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib116","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ejhg.2008.17","article-title":"Uptake of testing for BRCA1\/2 mutations in South East Scotland","volume":"16","author":"Holloway","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib117","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/gte.2007.0037","article-title":"Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1\/2 mutations","volume":"12","author":"Finlay","year":"2008","journal-title":"Genet Test"},{"key":"10.1016\/j.clon.2018.04.004_bib118","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10689-009-9313-1","article-title":"Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain","volume":"9","author":"Sanz","year":"2010","journal-title":"Fam Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib119","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1158\/1055-9965.EPI-10-0325","article-title":"Communication of BRCA results and family testing in 1,103 high-risk women","volume":"19","author":"Cheung","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clon.2018.04.004_bib120","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(95)91424-2","article-title":"Genetic testing in breast\/ovarian cancer (BRCA1) families","volume":"346","author":"Watson","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib121","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(00)02347-3","article-title":"Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation","volume":"355","author":"Meijers-Heijboer","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.04.004_bib122","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1155\/1999\/581346","article-title":"Uptake of genetic testing and pre-test levels of mental distress in Norwegian families with known BRCA1 mutations","volume":"15","author":"Reichelt","year":"1999","journal-title":"Dis Markers"},{"key":"10.1016\/j.clon.2018.04.004_bib123","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/1096-8628(20000814)93:4<257::AID-AJMG1>3.0.CO;2-8","article-title":"Psychosocial factors predicting BRCA1\/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families","volume":"93","author":"Bowles Biesecker","year":"2000","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib124","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1099-1611(200011\/12)9:6<522::AID-PON492>3.0.CO;2-S","article-title":"Proband family uptake of familial-genetic counselling","volume":"9","author":"Hagoel","year":"2000","journal-title":"Psychooncology"},{"key":"10.1016\/j.clon.2018.04.004_bib125","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1200\/JCO.2003.03.189","article-title":"American Society of Clinical Oncology Policy Statement Update: Genetic testing for cancer susceptibility","volume":"21","author":"ASCO Special Article","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib126","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1200\/JCO.2005.01.7541","article-title":"Sharing BRCA1\/2 test results with first-degree relatives: factors predicting who women tell","volume":"24","author":"Patenaude","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib127","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10689-013-9609-z","article-title":"Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial","volume":"12","author":"Montgomery","year":"2013","journal-title":"Familial Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib128","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2006.09.1900","article-title":"How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults","volume":"25","author":"Bradbury","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.GIM.0000144014.91237.A1","article-title":"Family communication about positive BRCA1 and BRCA2 genetic test results","volume":"6","author":"McGivern","year":"2004","journal-title":"Genet Med"},{"key":"10.1016\/j.clon.2018.04.004_bib130","article-title":"Do breast cancer patients tested in the oncology care setting share BRCA mutation results with family members and health care providers?","author":"Vadaparampil","year":"2012","journal-title":"J\u00a0Can Epidemiol"},{"key":"10.1016\/j.clon.2018.04.004_bib131","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cge.12468","article-title":"Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas","volume":"88","author":"Trottier","year":"2015","journal-title":"Clin Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib132","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s10897-012-9485-y","article-title":"Low rates of African American participation in genetic counseling and testing for BRCA1\/2 mutations: racial disparities or just a difference?","volume":"21","author":"Halbert","year":"2012","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.clon.2018.04.004_bib133","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajmg.a.10868","article-title":"Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients","volume":"1","author":"Claes","year":"2003","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clon.2018.04.004_bib134","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2018.04.004_bib135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/GIM.0b013e318163487d","article-title":"Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers","volume":"10","author":"Bradbury","year":"2008","journal-title":"Genet Med"},{"key":"10.1016\/j.clon.2018.04.004_bib136","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib137","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/gtmb.2008.0067","article-title":"Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers","volume":"13","author":"Beattie","year":"2009","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.clon.2018.04.004_bib138","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10689-012-9539-1","article-title":"Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome","volume":"11","author":"This","year":"2012","journal-title":"Fam Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib139","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/cncr.26294","article-title":"Long-term outcomes of BRCA1\/BRCA2 testing: risk reduction and surveillance","volume":"118","author":"Schwartz","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib140","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/bjc.2011.573","article-title":"Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women","volume":"106","author":"Sidon","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib141","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/2013.jamainternmed.962","article-title":"Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing","volume":"173","author":"Mannis","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clon.2018.04.004_bib142","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/cge.12149","article-title":"Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers","volume":"85","author":"Laitman","year":"2014","journal-title":"Clin Genet"},{"key":"10.1016\/j.clon.2018.04.004_bib143","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib144","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ygyno.2013.12.014","article-title":"Risk management options elected by women after testing positive for a BRCA mutation","volume":"132","author":"Garcia","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2016.07.104","article-title":"Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers: a single-center experience","volume":"143","author":"Harmsen","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clon.2018.04.004_bib146","first-page":"543","article-title":"BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations","volume":"8","author":"Finch","year":"2012","journal-title":"Womens Health"},{"key":"10.1016\/j.clon.2018.04.004_bib147","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00006250-200801000-00039","article-title":"ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy","volume":"111","author":"ACOG","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clon.2018.04.004_bib148","unstructured":"SGO clinical practice statement: Salpingectomy for ovarian cancer prevention. Available at: www.sgo.org\/clinical-practice\/guidelines\/sgo-clinical-practice-statement-salpingectomy-for-ovarian-prevention."},{"key":"10.1016\/j.clon.2018.04.004_bib149","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.29321","article-title":"Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer","volume":"121","author":"Walker","year":"2015","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.clon.2018.04.004_bib150","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-09-2953","article-title":"New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy","volume":"1","author":"Miller","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2018.04.004_bib151","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V","article-title":"Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women","volume":"92","author":"Julian-Reynier","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib152","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","article-title":"Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation","volume":"148","author":"Chai","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2018.04.004_bib153","first-page":"e92","article-title":"Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation","volume":"1","author":"Metcalfe","year":"2007","journal-title":"Open Med"},{"key":"10.1016\/j.clon.2018.04.004_bib154","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10897-009-9245-9","article-title":"Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review","volume":"18","author":"Howard","year":"2009","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.clon.2018.04.004_bib155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10689-012-9585-8","article-title":"Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer","volume":"12","author":"Meiser","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.clon.2018.04.004_bib156","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1471-0528.2011.03257.x","article-title":"Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis","volume":"119","author":"Manchanda","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.clon.2018.04.004_bib157","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/gim.2014.183","article-title":"Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1\/BRCA2 mutations","volume":"17","author":"Caiata-Zufferey","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.clon.2018.04.004_bib158","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.ejhg.5200418","article-title":"Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast\/ovarian cancer risk and subsequently published guidelines","volume":"8","author":"Julian-Reynier","year":"2000","journal-title":"Eur J Hum Genet"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518302139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518302139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:45:40Z","timestamp":1760543140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655518302139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":158,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0936655518302139"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2018.04.004","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}